Seattle Genetics | SGEN - SCHULD



SCHULD Veränderung Datum
AbbVie USD 67.5B 67.5B 2025-12
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Amgen USD 54.6B 17M 2025-12
Astellas Pharma JPY 831.43B 83.94B 2025-03
Bayer EUR 36.45B 2.93B 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Celldex Therapeutics USD 2.34M 285K 2025-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
Eisai JPY 236.67B 49.14B 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Exelixis USD 169.54M 3.5M 2026-03
Genmab DKK 148M 5M 2025-06
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 39.43M 982K 2026-03
Insmed USD 727.62M 275K 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 49.01B 2.02B 2026-06
Pfizer USD 63.73B 231M 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sanofi EUR 20.33B 1.43B 2025-12
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Takeda JPY 4.85T 208B 2025-12
Teva Pharmaceutical Industries USD 16.91B 187M 2026-03
Vertex Pharmaceuticals USD 1.99B 44M 2026-03
Xencor USD 187.75M 118.48M 2025-12